Anthony B. Evnin, Director at Juno Therapeutics, Inc. (JUNO), sold 227,354 shares at $48.26 ($10.9M) on 2015-07-27, disclosed to the SEC on 2015-07-29.
Scheduled sale ($10.9M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $47.82 | 146,614 | $7.0M | 64.3% |
| 2 | $48.26 | 80,740 | $3.9M | 35.7% |
| Total | $47.98 avg | 227,354 | $10.9M | 100% |
| Filing → |
| CNST | BUY | 2019-10-04 | $48.0M | — | Filing → |
| AVEO | BUY | 2018-11-26 | $223 | — | Filing → |
| AVEO | SELL | 2018-11-16 | $4.3M | — | Filing → |